A few years ago, @rweichselbaum posed—ironically, but not entirely so—the question: what is the difference between radiotherapy and radiosurgery? In some ways, this review attempts to answer that very question. This table provides a synopsis of its contents. #radonc

CTuscanoMD's tweet image. A few years ago, @rweichselbaum posed—ironically, but not entirely so—the question: what is the difference between radiotherapy and radiosurgery?
In some ways, this review attempts to answer that very question.
This table provides a synopsis of its contents. #radonc…

🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p<0.001) with minimal added adverse events. 🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine @ASTRO_org

_ShankarSiva's tweet image. 🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p&amp;lt;0.001) with minimal added adverse events. 
🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine @ASTRO_org
_ShankarSiva's tweet image. 🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p&amp;lt;0.001) with minimal added adverse events. 
🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine @ASTRO_org
_ShankarSiva's tweet image. 🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p&amp;lt;0.001) with minimal added adverse events. 
🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine @ASTRO_org

🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer! Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) & MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus #ASTRO25 #RadOnc

_ShankarSiva's tweet image. 🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer!

Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) &amp;amp; MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus 
#ASTRO25 #RadOnc
_ShankarSiva's tweet image. 🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer!

Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) &amp;amp; MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus 
#ASTRO25 #RadOnc
_ShankarSiva's tweet image. 🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer!

Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) &amp;amp; MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus 
#ASTRO25 #RadOnc
_ShankarSiva's tweet image. 🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer!

Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) &amp;amp; MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus 
#ASTRO25 #RadOnc

Reirradiation (reRT) is reshaping cancer care—offering hope for recurrent tumors w/ advanced precision techniques like IMRT & SBRT. Multidisciplinary care, imaging, and innovation are key. #OpenAccess review by Andratschke et al: acsjournals.onlinelibrary.wiley.com/doi/full/10.33… @OncoAlert #RadOnc

CACancerJournal's tweet image. Reirradiation (reRT) is reshaping cancer care—offering hope for recurrent tumors w/ advanced precision techniques like IMRT &amp;amp; SBRT. Multidisciplinary care, imaging, and innovation are key. 

#OpenAccess review by Andratschke et al:
acsjournals.onlinelibrary.wiley.com/doi/full/10.33…

@OncoAlert #RadOnc

WOW! 🧠METIS trial (n=298) in #lungcancer brain mets: SRS ➕ TTFields ⚡vs SRS alone ✅ TTFields delays intracranial progression (HR 0.72, p=0.044) 📉12-mo progression: 47% vs 59%; ⬆️ with immunotherapy (HR 0.63) ❌No QoL / cognition decline; AEs mild skin #ASTRO25 #RadOnc

_ShankarSiva's tweet image. WOW! 🧠METIS trial (n=298) in #lungcancer brain mets: SRS ➕ TTFields ⚡vs SRS alone
✅ TTFields delays intracranial progression (HR 0.72, p=0.044)
 📉12-mo progression: 47% vs 59%; ⬆️ with immunotherapy  (HR 0.63)
 ❌No QoL / cognition decline; AEs mild skin
#ASTRO25 #RadOnc…
_ShankarSiva's tweet image. WOW! 🧠METIS trial (n=298) in #lungcancer brain mets: SRS ➕ TTFields ⚡vs SRS alone
✅ TTFields delays intracranial progression (HR 0.72, p=0.044)
 📉12-mo progression: 47% vs 59%; ⬆️ with immunotherapy  (HR 0.63)
 ❌No QoL / cognition decline; AEs mild skin
#ASTRO25 #RadOnc…
_ShankarSiva's tweet image. WOW! 🧠METIS trial (n=298) in #lungcancer brain mets: SRS ➕ TTFields ⚡vs SRS alone
✅ TTFields delays intracranial progression (HR 0.72, p=0.044)
 📉12-mo progression: 47% vs 59%; ⬆️ with immunotherapy  (HR 0.63)
 ❌No QoL / cognition decline; AEs mild skin
#ASTRO25 #RadOnc…
_ShankarSiva's tweet image. WOW! 🧠METIS trial (n=298) in #lungcancer brain mets: SRS ➕ TTFields ⚡vs SRS alone
✅ TTFields delays intracranial progression (HR 0.72, p=0.044)
 📉12-mo progression: 47% vs 59%; ⬆️ with immunotherapy  (HR 0.63)
 ❌No QoL / cognition decline; AEs mild skin
#ASTRO25 #RadOnc…

Super excited to introduce #radonc who will be joining ⁦@CleClinicMD⁩ as staff in 2026- Drs. Meena Bedi, Saleh Hatoum, Mustafa Basree, Jenna Kocsis & Osagie Igiebor!! ⁦@ARRO_org#CleClinicCancer

DrJohnSuh's tweet image. Super excited to introduce #radonc who will be joining ⁦@CleClinicMD⁩ as staff in 2026- Drs. Meena Bedi, Saleh Hatoum, Mustafa Basree, Jenna Kocsis &amp;amp; Osagie Igiebor!! ⁦@ARRO_org⁩ #CleClinicCancer

🚀 POPART trial (n=100): Post-op SABR (32.5 Gy/5fx) for BCR after prostatectomy ✅ well-tolerated; late ≥G2 GU 7.5%, GI 1% 📉 2-yr BRFS ~79% (PSA ↓ to 0.028 ng/mL) ➡️SBRT prostate bed salvage = promising, needs longer follow-up. #ASTRO25 #RadOnc @ASTRO_org

_ShankarSiva's tweet image. 🚀 POPART trial (n=100): Post-op SABR (32.5 Gy/5fx) for BCR after prostatectomy
✅ well-tolerated; late ≥G2 GU 7.5%, GI 1%
📉 2-yr BRFS ~79% (PSA ↓ to 0.028 ng/mL)
➡️SBRT prostate bed salvage = promising, needs longer follow-up. #ASTRO25 #RadOnc @ASTRO_org
_ShankarSiva's tweet image. 🚀 POPART trial (n=100): Post-op SABR (32.5 Gy/5fx) for BCR after prostatectomy
✅ well-tolerated; late ≥G2 GU 7.5%, GI 1%
📉 2-yr BRFS ~79% (PSA ↓ to 0.028 ng/mL)
➡️SBRT prostate bed salvage = promising, needs longer follow-up. #ASTRO25 #RadOnc @ASTRO_org
_ShankarSiva's tweet image. 🚀 POPART trial (n=100): Post-op SABR (32.5 Gy/5fx) for BCR after prostatectomy
✅ well-tolerated; late ≥G2 GU 7.5%, GI 1%
📉 2-yr BRFS ~79% (PSA ↓ to 0.028 ng/mL)
➡️SBRT prostate bed salvage = promising, needs longer follow-up. #ASTRO25 #RadOnc @ASTRO_org
_ShankarSiva's tweet image. 🚀 POPART trial (n=100): Post-op SABR (32.5 Gy/5fx) for BCR after prostatectomy
✅ well-tolerated; late ≥G2 GU 7.5%, GI 1%
📉 2-yr BRFS ~79% (PSA ↓ to 0.028 ng/mL)
➡️SBRT prostate bed salvage = promising, needs longer follow-up. #ASTRO25 #RadOnc @ASTRO_org

Terrific surprise to have ⁦@SameerKeoleMD⁩ ⁦@ASTRO_Chair⁩ ⁦@MayoRadOnc⁩ spend time with #radonc@ABR_Radiology⁩ Board members in Phoenix!! Congrats on a very successful & informative ⁦@ASTRO_org⁩ meeting on reimagining radiation medicine! ⁦⁦

DrJohnSuh's tweet image. Terrific surprise to have ⁦@SameerKeoleMD⁩ ⁦@ASTRO_Chair⁩ ⁦@MayoRadOnc⁩ spend time with #radonc ⁦@ABR_Radiology⁩ Board members in Phoenix!! Congrats on a very successful &amp;amp; informative ⁦@ASTRO_org⁩ meeting on reimagining radiation medicine! ⁦⁦

Truly an honor to be invited to Mt Sinai to speak, 9 years after finishing my residency @ken4englewood @MSROResidents #radonc #fullcircle

MKnoll_MD's tweet image. Truly an honor to be invited to Mt Sinai to speak, 9 years after finishing my residency 

@ken4englewood @MSROResidents

#radonc #fullcircle

What do all these radiation oncologists have in common? #radonc

ACKoongMDPhD's tweet image. What do all these radiation oncologists have in common? #radonc

Hanging out with the ⁦@MDAndersonNews#radonc residents at the after party. #ASTRO25@PrajnanDasMD⁩ ⁦@ChelseaPinnix⁩ ⁦@yogagirldd

ACKoongMDPhD's tweet image. Hanging out with the ⁦@MDAndersonNews⁩ #radonc residents at the after party. #ASTRO25 ⁦@PrajnanDasMD⁩ ⁦@ChelseaPinnix⁩ ⁦@yogagirldd⁩

Great to have the chance to meet with the amazing #RadOnc residents @UofTDRO during their academic half day and then enjoy a fun lunch together @ldawsonmd

DKirschMDPhD's tweet image. Great to have the chance to meet with the amazing #RadOnc residents @UofTDRO during their academic half day and then enjoy a fun lunch together

@ldawsonmd

I had an amazing time returning to the old residency stomping grounds and seeing the new facility as visiting professor and BCM #radonc. Met a great group of residents and discussed optimization of #brachytherapy workflows!

AndrewFarach's tweet image. I had an amazing time returning to the old residency stomping grounds and seeing the new facility as visiting professor and BCM #radonc. Met a great group of residents and discussed optimization of #brachytherapy workflows!

Work outfit. Because even on cloudy rainy days you gotta bring patients your own sunshine ☀️😎🧬☢️. #RadOnc #gyncsm

IvyRadOncMD's tweet image. Work outfit. Because even on cloudy rainy days you gotta bring patients your own sunshine ☀️😎🧬☢️. #RadOnc #gyncsm

Lab members Jared Gregston, Dr. @TheDrWood, & @MayaJanel in front of their #RadOnc #BreastCancer work at #ASCOQLTY25. Congrats to Jared on the Merit Award!

DrMcClellandLab's tweet image. Lab members Jared Gregston, Dr. @TheDrWood, &amp;amp; @MayaJanel in front of their #RadOnc #BreastCancer work at #ASCOQLTY25. 
Congrats to Jared on the Merit Award!
DrMcClellandLab's tweet image. Lab members Jared Gregston, Dr. @TheDrWood, &amp;amp; @MayaJanel in front of their #RadOnc #BreastCancer work at #ASCOQLTY25. 
Congrats to Jared on the Merit Award!

One of my favorite parts of #radonc ☢️ training at @MDAndersonNews has been to train alongside amazing #womenwhocurie. Having 👯‍♀️ who support you at work & in your personal life makes all the difference. Wouldn’t want to learn how to make cancer history with anyone else! ❤️

StephDudzinski's tweet image. One of my favorite parts of #radonc ☢️ training at @MDAndersonNews has been to train alongside amazing #womenwhocurie. 

Having 👯‍♀️ who support you at work &amp;amp; in your personal life makes all the difference. 

Wouldn’t want to learn how to make cancer history with anyone else! ❤️

The best time to update your academic CV is on the flight back from a conference #ASTRO25 #radonc Use our CV and cover letter writing guide via @ASTRO_org @ARRO_org @CWRUSOM @DrChrisCorso @yazshaz Slides: docs.google.com/presentation/d… Talk: astro.org/interest-group…

NicholasZaorsky's tweet image. The best time to update your academic CV is on the flight back from a conference
#ASTRO25 #radonc

Use our CV and cover letter writing guide via @ASTRO_org @ARRO_org @CWRUSOM 
@DrChrisCorso @yazshaz

Slides: docs.google.com/presentation/d…

Talk:
astro.org/interest-group…
NicholasZaorsky's tweet image. The best time to update your academic CV is on the flight back from a conference
#ASTRO25 #radonc

Use our CV and cover letter writing guide via @ASTRO_org @ARRO_org @CWRUSOM 
@DrChrisCorso @yazshaz

Slides: docs.google.com/presentation/d…

Talk:
astro.org/interest-group…

"When Disaster Strikes: Maintaining Cancer Care During Catastrophic Events" Proud of this panel @ASCO #ASCOQLTY25 including 3⃣ #radonc. Radiation care is a vital cancer treatment involving DAILY visits; disruptions during catastrophic events disproportionately effects our care.

fumikochino's tweet image. &quot;When Disaster Strikes: Maintaining Cancer Care During Catastrophic Events&quot; 

Proud of this panel @ASCO #ASCOQLTY25 including 3⃣ #radonc. Radiation care is a vital cancer treatment involving DAILY visits; disruptions during catastrophic events disproportionately effects our care.

See how Vincent Bourbonne, MD, PhD, #RadOnc physician at Centre Hospitalier Universitaire de Brest, France, effectively handles the complexity of #Reirradiation cases with MIM Maestro™. ▶️ Watch the on-demand webinar now: bit.ly/4qqgh1R

mimsoftware's tweet image. See how Vincent Bourbonne, MD, PhD, #RadOnc physician at Centre Hospitalier Universitaire de Brest, France, effectively handles the complexity of #Reirradiation cases with MIM Maestro™.

▶️ Watch the on-demand webinar now: bit.ly/4qqgh1R

And this is the reason why it is so important to #connect in #collaborate. @RTOGFoundation @NRGonc offers an unparalleled platform to advanced Radiation Medicine frontiers! @StephenChunMD #RadOnc #MedOnc #SurgOnc @NSABPFoundation #Medicine

Our RTOGF Interns interviewed @StephenChunMD - Director of Radiation Oncology Clinical Research at MD Anderson Houston area locations and co-founder of the NRG Oncology Podcast - on his career & advice for early career investigators. Read more: ow.ly/PvaF50X7Ttn

RTOGFoundation's tweet image. Our RTOGF Interns interviewed @StephenChunMD - Director of Radiation Oncology Clinical Research at MD Anderson Houston area locations and co-founder of the NRG Oncology Podcast - on his career &amp;amp; advice for early career investigators. Read more: ow.ly/PvaF50X7Ttn


One month out from the 2025 @MDAndersonNews Boot Walk to #endcancer. Join the #radonc team and walk with us on Nov 15th at the TMC! I'm supporting The University of Texas MD Anderson Cancer Center! do.nr/7v2tj9t0 via @DonorDrive


The 10-year biochemical DFS rate was 86% with EBRT plus focal boost vs 71% with standard EBRT in those with intermediate- and high-risk prostate cancer. hubs.li/Q03N942N0 #pcsm #cancer #RadOnc


Ojo! en contextos clínicos localizados —como un hospital o área sanitaria concreta— ese “sobreajuste” puede ser funcional si el objetivo del modelo es optimizar decisiones dentro de esa misma población. #radonc #datascience #algorithms #DeepLearning #machinelearning

FREELANCEROG's tweet image. Ojo! 
en contextos clínicos localizados —como un hospital o área sanitaria concreta— ese “sobreajuste” puede ser funcional si el objetivo del modelo es optimizar decisiones dentro de esa misma población.
#radonc
#datascience #algorithms #DeepLearning #machinelearning

I love #radonc and radiosurgery because of the empiric outcomes. But we need to stop claiming <1 mm accuracy when our tech specs say the imaging has 2 mm resolution. Maybe can claim specifically <1 mm setup error…

A few years ago, @rweichselbaum posed—ironically, but not entirely so—the question: what is the difference between radiotherapy and radiosurgery? In some ways, this review attempts to answer that very question. This table provides a synopsis of its contents. #radonc

CTuscanoMD's tweet image. A few years ago, @rweichselbaum posed—ironically, but not entirely so—the question: what is the difference between radiotherapy and radiosurgery?
In some ways, this review attempts to answer that very question.
This table provides a synopsis of its contents. #radonc…


A few years ago, @rweichselbaum posed—ironically, but not entirely so—the question: what is the difference between radiotherapy and radiosurgery? In some ways, this review attempts to answer that very question. This table provides a synopsis of its contents. #radonc

CTuscanoMD's tweet image. A few years ago, @rweichselbaum posed—ironically, but not entirely so—the question: what is the difference between radiotherapy and radiosurgery?
In some ways, this review attempts to answer that very question.
This table provides a synopsis of its contents. #radonc…

We have theoretical physicists. Do we have theoretical radiation oncologists? #radonc #radmed @NehaVapiwala @HenningWillers @NiuSanford @sueyom @rweichselbaum @SameerKeoleMD @pipcosper @KimpleRandall


"When Disaster Strikes: Maintaining Cancer Care During Catastrophic Events" Proud of this panel @ASCO #ASCOQLTY25 including 3⃣ #radonc. Radiation care is a vital cancer treatment involving DAILY visits; disruptions during catastrophic events disproportionately effects our care.

fumikochino's tweet image. &quot;When Disaster Strikes: Maintaining Cancer Care During Catastrophic Events&quot; 

Proud of this panel @ASCO #ASCOQLTY25 including 3⃣ #radonc. Radiation care is a vital cancer treatment involving DAILY visits; disruptions during catastrophic events disproportionately effects our care.

☢️ Radiation Oncologist Prof Sandra Turner & Clinical Oncologist Dr Katie Wakeham talk about the purpose of World Radiotherapy Awareness Day & the Global Movement to make sure cancer patients get access to #radiotherapy if needed. @WorldRTDay #radonc #rtt youtu.be/TvJakDH1DSo

JulieMcCrossin's tweet card. World Radiotherapy Awareness Day - Interview with Prof Sandra Turner...

youtube.com

YouTube

World Radiotherapy Awareness Day - Interview with Prof Sandra Turner...


Work by Drs @KShah0520 & @TrishaSantosMD using the NIS sample showed incarcerated adults in the US are 92% more likely to die from their cancer than the non-incarcerated. Cancer is the #1 cause of death in hospitalized incarcerated patients‼️‼️ #ASCOQLTY25

anhbl9's tweet image. Work by Drs @KShah0520 &amp;amp; @TrishaSantosMD using the NIS sample showed incarcerated adults in the US are 92% more likely to die from their cancer than the non-incarcerated.

Cancer is the #1 cause of death in hospitalized incarcerated patients‼️‼️

#ASCOQLTY25
anhbl9's tweet image. Work by Drs @KShah0520 &amp;amp; @TrishaSantosMD using the NIS sample showed incarcerated adults in the US are 92% more likely to die from their cancer than the non-incarcerated.

Cancer is the #1 cause of death in hospitalized incarcerated patients‼️‼️

#ASCOQLTY25
anhbl9's tweet image. Work by Drs @KShah0520 &amp;amp; @TrishaSantosMD using the NIS sample showed incarcerated adults in the US are 92% more likely to die from their cancer than the non-incarcerated.

Cancer is the #1 cause of death in hospitalized incarcerated patients‼️‼️

#ASCOQLTY25


Fantastic mentee, @DrMcClellandLab member & @OUCollegeofMed MS4 Jared Gregston presenting his @ConquerCancerFd Merit Award-winning work on the rate & quality of #BreastCancer care following initial diagnosis at #ASCOQLTY25! #RadOnc #bcsm #RepresentationMatters #Match2026

TheDrWood's tweet image. Fantastic mentee, @DrMcClellandLab member &amp;amp; @OUCollegeofMed MS4 Jared Gregston presenting his @ConquerCancerFd Merit Award-winning work on the rate &amp;amp; quality of #BreastCancer care following initial diagnosis at #ASCOQLTY25!
#RadOnc
#bcsm
#RepresentationMatters
#Match2026
TheDrWood's tweet image. Fantastic mentee, @DrMcClellandLab member &amp;amp; @OUCollegeofMed MS4 Jared Gregston presenting his @ConquerCancerFd Merit Award-winning work on the rate &amp;amp; quality of #BreastCancer care following initial diagnosis at #ASCOQLTY25!
#RadOnc
#bcsm
#RepresentationMatters
#Match2026
TheDrWood's tweet image. Fantastic mentee, @DrMcClellandLab member &amp;amp; @OUCollegeofMed MS4 Jared Gregston presenting his @ConquerCancerFd Merit Award-winning work on the rate &amp;amp; quality of #BreastCancer care following initial diagnosis at #ASCOQLTY25!
#RadOnc
#bcsm
#RepresentationMatters
#Match2026

Lab members Jared Gregston, Dr. @TheDrWood, & @MayaJanel in front of their #RadOnc #BreastCancer work at #ASCOQLTY25. Congrats to Jared on the Merit Award!

DrMcClellandLab's tweet image. Lab members Jared Gregston, Dr. @TheDrWood, &amp;amp; @MayaJanel in front of their #RadOnc #BreastCancer work at #ASCOQLTY25. 
Congrats to Jared on the Merit Award!
DrMcClellandLab's tweet image. Lab members Jared Gregston, Dr. @TheDrWood, &amp;amp; @MayaJanel in front of their #RadOnc #BreastCancer work at #ASCOQLTY25. 
Congrats to Jared on the Merit Award!

Today at #ASCOQLTY25: lab members Jared Gregston (MS4 @OUCollegeofMed) & Maya Stephens (@MayaJanel; MS2 @MCG_AUG) present their accepted abstracts (with caffeinated assistance)! #RadOnc

DrMcClellandLab's tweet image. Today at #ASCOQLTY25: lab members Jared Gregston (MS4 @OUCollegeofMed) &amp;amp; Maya Stephens (@MayaJanel; MS2 @MCG_AUG) present their accepted abstracts (with caffeinated assistance)!
#RadOnc

🌟 A heartfelt gratitude to the incredible #radonc team at the Miami Cancer Institute. A special thanks to Drs. Matthew Hall, Minesh Mehta, Alonso Gutierrez, wonderful admins Marina & Juliet, & the whole team for the warm invitation & exceptional hospitality during my visit.

NataliyaMedPhys's tweet image. 🌟 A heartfelt gratitude to the incredible #radonc team at the Miami Cancer Institute. A special thanks to Drs. Matthew Hall, Minesh Mehta, Alonso Gutierrez, wonderful admins Marina &amp;amp; Juliet, &amp;amp; the whole team for the warm invitation &amp;amp; exceptional hospitality during my visit.
NataliyaMedPhys's tweet image. 🌟 A heartfelt gratitude to the incredible #radonc team at the Miami Cancer Institute. A special thanks to Drs. Matthew Hall, Minesh Mehta, Alonso Gutierrez, wonderful admins Marina &amp;amp; Juliet, &amp;amp; the whole team for the warm invitation &amp;amp; exceptional hospitality during my visit.

Beyond grateful to @RTOGFoundation for this unparalleled opportunity to work with, and learn about the inner workings of, a core founding member of @NRGonc with more than six decades of history pioneering the standards of care in #radonc! @wallyjc @KHigginsMD @Qle_stanford

We cannot be more grateful for our RTOG Foundation Communications Interns each year that help our Communications Committee expand the reach of the important messages RTOGF shares. Learn more about our 2025-2026 interns, @djlee714 & @AlexisNarvaezMD here: ow.ly/Euji50X7PYI

RTOGFoundation's tweet image. We cannot be more grateful for our RTOG Foundation Communications Interns each year that help our Communications Committee expand the reach of the important messages RTOGF shares. Learn more about our 2025-2026 interns, @djlee714 &amp;amp; @AlexisNarvaezMD here: ow.ly/Euji50X7PYI


Tomorrow 10/11/2025 11:50AM EST I will be presenting my locoregional perspective of the evolution of Breast Cancer treatment. The #SurgOnc and #RadOnc perspective. Full #Spanish talk as part of my #GlobalHealth #LatAm #efforts as an #international accredited #surgonc #faculty.…

AlexisNarvaezMD's tweet image. Tomorrow 10/11/2025 11:50AM EST I will be presenting my locoregional perspective of the evolution of Breast Cancer treatment. The #SurgOnc and #RadOnc perspective. Full #Spanish talk as part of my #GlobalHealth #LatAm #efforts as an #international accredited #surgonc #faculty.…
AlexisNarvaezMD's tweet image. Tomorrow 10/11/2025 11:50AM EST I will be presenting my locoregional perspective of the evolution of Breast Cancer treatment. The #SurgOnc and #RadOnc perspective. Full #Spanish talk as part of my #GlobalHealth #LatAm #efforts as an #international accredited #surgonc #faculty.…
AlexisNarvaezMD's tweet image. Tomorrow 10/11/2025 11:50AM EST I will be presenting my locoregional perspective of the evolution of Breast Cancer treatment. The #SurgOnc and #RadOnc perspective. Full #Spanish talk as part of my #GlobalHealth #LatAm #efforts as an #international accredited #surgonc #faculty.…
AlexisNarvaezMD's tweet image. Tomorrow 10/11/2025 11:50AM EST I will be presenting my locoregional perspective of the evolution of Breast Cancer treatment. The #SurgOnc and #RadOnc perspective. Full #Spanish talk as part of my #GlobalHealth #LatAm #efforts as an #international accredited #surgonc #faculty.…

Great turnout to learn about cancer biology science @SitemanCenter Research Symposium! The #radonc labs of @JulieSchwarz14 & @VKapoor25 were well-represented at the podium.

WashUMedRadOnc's tweet image. Great turnout to learn about cancer biology science @SitemanCenter Research Symposium! 
The #radonc labs of @JulieSchwarz14 &amp;amp; @VKapoor25 were well-represented at the podium.
WashUMedRadOnc's tweet image. Great turnout to learn about cancer biology science @SitemanCenter Research Symposium! 
The #radonc labs of @JulieSchwarz14 &amp;amp; @VKapoor25 were well-represented at the podium.

We're excited to introduce our new 2025 Radiation Oncology Fellows at @UofTDRO! 📷Learn more about them: uoft.me/newfellow2025 @jenncroke #radonc #UofTDRO

UofTDRO's tweet image. We&apos;re excited to introduce our new 2025 Radiation Oncology Fellows at @UofTDRO! 📷Learn more about them: uoft.me/newfellow2025
@jenncroke #radonc #UofTDRO

🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p<0.001) with minimal added adverse events. 🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine @ASTRO_org

_ShankarSiva's tweet image. 🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p&amp;lt;0.001) with minimal added adverse events. 
🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine @ASTRO_org
_ShankarSiva's tweet image. 🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p&amp;lt;0.001) with minimal added adverse events. 
🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine @ASTRO_org
_ShankarSiva's tweet image. 🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p&amp;lt;0.001) with minimal added adverse events. 
🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine @ASTRO_org

Reirradiation (reRT) is reshaping cancer care—offering hope for recurrent tumors w/ advanced precision techniques like IMRT & SBRT. Multidisciplinary care, imaging, and innovation are key. #OpenAccess review by Andratschke et al: acsjournals.onlinelibrary.wiley.com/doi/full/10.33… @OncoAlert #RadOnc

CACancerJournal's tweet image. Reirradiation (reRT) is reshaping cancer care—offering hope for recurrent tumors w/ advanced precision techniques like IMRT &amp;amp; SBRT. Multidisciplinary care, imaging, and innovation are key. 

#OpenAccess review by Andratschke et al:
acsjournals.onlinelibrary.wiley.com/doi/full/10.33…

@OncoAlert #RadOnc

One of my favorite parts of #radonc ☢️ training at @MDAndersonNews has been to train alongside amazing #womenwhocurie. Having 👯‍♀️ who support you at work & in your personal life makes all the difference. Wouldn’t want to learn how to make cancer history with anyone else! ❤️

StephDudzinski's tweet image. One of my favorite parts of #radonc ☢️ training at @MDAndersonNews has been to train alongside amazing #womenwhocurie. 

Having 👯‍♀️ who support you at work &amp;amp; in your personal life makes all the difference. 

Wouldn’t want to learn how to make cancer history with anyone else! ❤️

A few years ago, @rweichselbaum posed—ironically, but not entirely so—the question: what is the difference between radiotherapy and radiosurgery? In some ways, this review attempts to answer that very question. This table provides a synopsis of its contents. #radonc

CTuscanoMD's tweet image. A few years ago, @rweichselbaum posed—ironically, but not entirely so—the question: what is the difference between radiotherapy and radiosurgery?
In some ways, this review attempts to answer that very question.
This table provides a synopsis of its contents. #radonc…

Hanging out with the ⁦@MDAndersonNews#radonc residents at the after party. #ASTRO25@PrajnanDasMD⁩ ⁦@ChelseaPinnix⁩ ⁦@yogagirldd

ACKoongMDPhD's tweet image. Hanging out with the ⁦@MDAndersonNews⁩ #radonc residents at the after party. #ASTRO25 ⁦@PrajnanDasMD⁩ ⁦@ChelseaPinnix⁩ ⁦@yogagirldd⁩

Happy to share that my K08 award scored in the 2nd percentile on our first submission- grateful for all of our collaborators and excited for the work to come! #radonc @UMRogelCancer @MichRadOncRes @YatrikShahLab @DanWahlMD @Dan_ChangMD @UMichRadOnc

ameerelaimy's tweet image. Happy to share that my K08 award scored in the 2nd percentile on our first submission- grateful for all of our collaborators and excited for the work to come! #radonc @UMRogelCancer @MichRadOncRes @YatrikShahLab @DanWahlMD @Dan_ChangMD @UMichRadOnc

🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer! Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) & MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus #ASTRO25 #RadOnc

_ShankarSiva's tweet image. 🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer!

Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) &amp;amp; MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus 
#ASTRO25 #RadOnc
_ShankarSiva's tweet image. 🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer!

Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) &amp;amp; MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus 
#ASTRO25 #RadOnc
_ShankarSiva's tweet image. 🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer!

Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) &amp;amp; MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus 
#ASTRO25 #RadOnc
_ShankarSiva's tweet image. 🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer!

Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) &amp;amp; MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus 
#ASTRO25 #RadOnc

#ASTRO25 has been wonderful to connect with the North American and international #radonc community…. 🙏🏽 for the memories! 😁

_ShankarSiva's tweet image. #ASTRO25 has been wonderful to connect with the North American and international #radonc community…. 🙏🏽 for the memories! 😁
_ShankarSiva's tweet image. #ASTRO25 has been wonderful to connect with the North American and international #radonc community…. 🙏🏽 for the memories! 😁
_ShankarSiva's tweet image. #ASTRO25 has been wonderful to connect with the North American and international #radonc community…. 🙏🏽 for the memories! 😁
_ShankarSiva's tweet image. #ASTRO25 has been wonderful to connect with the North American and international #radonc community…. 🙏🏽 for the memories! 😁

What do all these radiation oncologists have in common? #radonc

ACKoongMDPhD's tweet image. What do all these radiation oncologists have in common? #radonc

WOW! 🧠METIS trial (n=298) in #lungcancer brain mets: SRS ➕ TTFields ⚡vs SRS alone ✅ TTFields delays intracranial progression (HR 0.72, p=0.044) 📉12-mo progression: 47% vs 59%; ⬆️ with immunotherapy (HR 0.63) ❌No QoL / cognition decline; AEs mild skin #ASTRO25 #RadOnc

_ShankarSiva's tweet image. WOW! 🧠METIS trial (n=298) in #lungcancer brain mets: SRS ➕ TTFields ⚡vs SRS alone
✅ TTFields delays intracranial progression (HR 0.72, p=0.044)
 📉12-mo progression: 47% vs 59%; ⬆️ with immunotherapy  (HR 0.63)
 ❌No QoL / cognition decline; AEs mild skin
#ASTRO25 #RadOnc…
_ShankarSiva's tweet image. WOW! 🧠METIS trial (n=298) in #lungcancer brain mets: SRS ➕ TTFields ⚡vs SRS alone
✅ TTFields delays intracranial progression (HR 0.72, p=0.044)
 📉12-mo progression: 47% vs 59%; ⬆️ with immunotherapy  (HR 0.63)
 ❌No QoL / cognition decline; AEs mild skin
#ASTRO25 #RadOnc…
_ShankarSiva's tweet image. WOW! 🧠METIS trial (n=298) in #lungcancer brain mets: SRS ➕ TTFields ⚡vs SRS alone
✅ TTFields delays intracranial progression (HR 0.72, p=0.044)
 📉12-mo progression: 47% vs 59%; ⬆️ with immunotherapy  (HR 0.63)
 ❌No QoL / cognition decline; AEs mild skin
#ASTRO25 #RadOnc…
_ShankarSiva's tweet image. WOW! 🧠METIS trial (n=298) in #lungcancer brain mets: SRS ➕ TTFields ⚡vs SRS alone
✅ TTFields delays intracranial progression (HR 0.72, p=0.044)
 📉12-mo progression: 47% vs 59%; ⬆️ with immunotherapy  (HR 0.63)
 ❌No QoL / cognition decline; AEs mild skin
#ASTRO25 #RadOnc…

🚀 POPART trial (n=100): Post-op SABR (32.5 Gy/5fx) for BCR after prostatectomy ✅ well-tolerated; late ≥G2 GU 7.5%, GI 1% 📉 2-yr BRFS ~79% (PSA ↓ to 0.028 ng/mL) ➡️SBRT prostate bed salvage = promising, needs longer follow-up. #ASTRO25 #RadOnc @ASTRO_org

_ShankarSiva's tweet image. 🚀 POPART trial (n=100): Post-op SABR (32.5 Gy/5fx) for BCR after prostatectomy
✅ well-tolerated; late ≥G2 GU 7.5%, GI 1%
📉 2-yr BRFS ~79% (PSA ↓ to 0.028 ng/mL)
➡️SBRT prostate bed salvage = promising, needs longer follow-up. #ASTRO25 #RadOnc @ASTRO_org
_ShankarSiva's tweet image. 🚀 POPART trial (n=100): Post-op SABR (32.5 Gy/5fx) for BCR after prostatectomy
✅ well-tolerated; late ≥G2 GU 7.5%, GI 1%
📉 2-yr BRFS ~79% (PSA ↓ to 0.028 ng/mL)
➡️SBRT prostate bed salvage = promising, needs longer follow-up. #ASTRO25 #RadOnc @ASTRO_org
_ShankarSiva's tweet image. 🚀 POPART trial (n=100): Post-op SABR (32.5 Gy/5fx) for BCR after prostatectomy
✅ well-tolerated; late ≥G2 GU 7.5%, GI 1%
📉 2-yr BRFS ~79% (PSA ↓ to 0.028 ng/mL)
➡️SBRT prostate bed salvage = promising, needs longer follow-up. #ASTRO25 #RadOnc @ASTRO_org
_ShankarSiva's tweet image. 🚀 POPART trial (n=100): Post-op SABR (32.5 Gy/5fx) for BCR after prostatectomy
✅ well-tolerated; late ≥G2 GU 7.5%, GI 1%
📉 2-yr BRFS ~79% (PSA ↓ to 0.028 ng/mL)
➡️SBRT prostate bed salvage = promising, needs longer follow-up. #ASTRO25 #RadOnc @ASTRO_org

Super excited to introduce #radonc who will be joining ⁦@CleClinicMD⁩ as staff in 2026- Drs. Meena Bedi, Saleh Hatoum, Mustafa Basree, Jenna Kocsis & Osagie Igiebor!! ⁦@ARRO_org#CleClinicCancer

DrJohnSuh's tweet image. Super excited to introduce #radonc who will be joining ⁦@CleClinicMD⁩ as staff in 2026- Drs. Meena Bedi, Saleh Hatoum, Mustafa Basree, Jenna Kocsis &amp;amp; Osagie Igiebor!! ⁦@ARRO_org⁩ #CleClinicCancer

Great to have the chance to meet with the amazing #RadOnc residents @UofTDRO during their academic half day and then enjoy a fun lunch together @ldawsonmd

DKirschMDPhD's tweet image. Great to have the chance to meet with the amazing #RadOnc residents @UofTDRO during their academic half day and then enjoy a fun lunch together

@ldawsonmd

Honored to train at ⁦@MSKCancerCenter#radonc alongside experts, change makers, and good people 🤩 #ASTRO2025@ASTRO_org⁩ ⁦@DanielGorovets⁩ ⁦@seanmmcbride⁩ ⁦@KaitlynLapen⁩ ⁦@MSK_RadOnc⁩ Thank you to Melissa and Amelia for setting this up

EChrisDee's tweet image. Honored to train at ⁦@MSKCancerCenter⁩ #radonc alongside experts, change makers, and good people 🤩

#ASTRO2025 ⁦@ASTRO_org⁩ 

⁦@DanielGorovets⁩ ⁦@seanmmcbride⁩ ⁦@KaitlynLapen⁩ ⁦@MSK_RadOnc⁩ 

Thank you to Melissa and Amelia for setting this up

Humbled & honored to join @ASTRO_org ’s Int’l Executive Committee for 2025-2026! This help shape global cancer care strategies, empower underserved & drive ASTRO’s mission. Thrilled to collaborate with leaders at #ASTRO2025! Grateful for the trust #RadOnc @KFSHRC @SARO_KSA

draldehaim's tweet image. Humbled &amp;amp; honored to join @ASTRO_org ’s Int’l Executive Committee for 2025-2026! 
This help shape global cancer care strategies, empower underserved &amp;amp; drive ASTRO’s mission. Thrilled to collaborate with leaders at #ASTRO2025!  

Grateful for the trust
#RadOnc
 @KFSHRC 
@SARO_KSA
draldehaim's tweet image. Humbled &amp;amp; honored to join @ASTRO_org ’s Int’l Executive Committee for 2025-2026! 
This help shape global cancer care strategies, empower underserved &amp;amp; drive ASTRO’s mission. Thrilled to collaborate with leaders at #ASTRO2025!  

Grateful for the trust
#RadOnc
 @KFSHRC 
@SARO_KSA

I had an amazing time returning to the old residency stomping grounds and seeing the new facility as visiting professor and BCM #radonc. Met a great group of residents and discussed optimization of #brachytherapy workflows!

AndrewFarach's tweet image. I had an amazing time returning to the old residency stomping grounds and seeing the new facility as visiting professor and BCM #radonc. Met a great group of residents and discussed optimization of #brachytherapy workflows!

Truly an honor to be invited to Mt Sinai to speak, 9 years after finishing my residency @ken4englewood @MSROResidents #radonc #fullcircle

MKnoll_MD's tweet image. Truly an honor to be invited to Mt Sinai to speak, 9 years after finishing my residency 

@ken4englewood @MSROResidents

#radonc #fullcircle

Lab members Jared Gregston, Dr. @TheDrWood, & @MayaJanel in front of their #RadOnc #BreastCancer work at #ASCOQLTY25. Congrats to Jared on the Merit Award!

DrMcClellandLab's tweet image. Lab members Jared Gregston, Dr. @TheDrWood, &amp;amp; @MayaJanel in front of their #RadOnc #BreastCancer work at #ASCOQLTY25. 
Congrats to Jared on the Merit Award!
DrMcClellandLab's tweet image. Lab members Jared Gregston, Dr. @TheDrWood, &amp;amp; @MayaJanel in front of their #RadOnc #BreastCancer work at #ASCOQLTY25. 
Congrats to Jared on the Merit Award!

Loading...

Something went wrong.


Something went wrong.


United States Trends